Loading...
Our Company 2017-04-12T02:09:22+00:00

Cancer is a complex disease, and for therapies to be maximally effective and tolerable, they must distinguish between normal and cancerous cells. Advanced Proteome Therapeutics Corporation is developing a proprietary technology to directly target cancerous tumors and avoid destroying normal cells. This type of agent is capable of greater potency, higher specificity, and lower toxicity than other therapies that can also attack healthy cells, Advanced Proteome is working to streamline the process by which these agents are prepared, which to date, has been extremely cumbersome, limiting the potential of this type of agent.

Our People

Dr. Allen (Alexander) Krantz

Dr. Allen (Alexander) Krantz

Founder, CSO and VP Research

Allen Krantz has had an extensive career in academia and industry. From 1968 to 1980, he was a member of the Faculty of Chemistry at Stony Brook University, holding appointments in both the Department of Chemistry, and the Department of Pharmacological Sciences in the University’s Medical School. From 1981 to 1994, Dr. Krantz was Director, and then Vice-President of Research at Syntex Research Canada and held Adjunct Professorships during this period at the Universities of Toronto and Guelph while holding the title of Distinguished Scientist at the Corporation… From 1994 to 1997, Dr. Krantz served as Executive Vice President of Research at RedCell, Inc., the forerunner of ConjuChem, (TSX: CJC), and served as the Directeur Scientifique of the European office in France during the same period. Dr. Krantz was responsible for transforming the company’s program to a practical focal point on human serum albumin as a carrier of drugs. He is also a Founder, and served as the inaugural President of Pharmena North America Incorporated, a privately held, biotechnology company. Dr. Krantz obtained his Masters of Science and Ph.D. degrees from Yale University.

Dr. Randal Chase

Dr. Randal Chase

President and CEO

Dr. Chase has more than 40 years of experience in biotechnology and related fields. Randal began his career at Bristol Meyers and Glaxo Canada Inc., where he held the positions of Director and Senior Vice President, respectively. He is a former President of several companies, including Quadra Logic Technologies, Inc., North American Vaccine and Aventis Pasteur Canada. As well, Dr. Chase has served as President and Chief Executive Officer of ImmunoVaccine Technologies Inc. from 2006 to 2011. From 2005 to 2006, he was Chairman of the Board of Directors of Molecular Templates Inc. From 2001 to 2004, Dr. Chase was President of Shire Biologics Inc and from May 2001 to August 2002, he served as Senior Vice-President, Vaccines Operations of Biochem Pharma Inc. Among his numerous appointments, Dr. Chase has been a member of the board of Biotech Canada, and has served as a Director of Bioject Medical Technologies, Inc. (NASDAQ), Acambis PLC (London Stock Exchange, NASDAQ), and of Conjuchem Inc. and of Conjuchem Biotechnologies Inc. (TSX). Most recently, Dr. Chase was Chairman of the Board and Director of Medicago. He currently serves as Chairman of MediMabs, a privately held company, and is a member of the Board of Geovax Labs, Inc., a vaccine company trading on the OTCQX.

Kenneth C. Phillippe, B. Comm, CA

Kenneth C. Phillippe, B. Comm, CA

Chief Financial Officer

Mr. Phillippe is a Chartered Accountant with over 25 years’ experience working with public companies in the capacities of director, officer, financial advisor or consultant. Mr. Phillippe obtained a Bachelor of Commerce degree from the University of British Columbia in 1976. He articled with Thorne Riddell (now KPMG) and in1982 established his own accounting practice. During the period from February, 2000 to 2008, Mr. Phillippe held several high level Executive positions including director, officer, and chair of the audit committee of Urodynamix Technologies Ltd. (TSX – (URO.V))., CFO of Columbia Goldfields Ltd. (TSX – (GOL.TO) / OTCBB –(CGDF)), as Secretary, Treasurer, CFO and Principal Accounting Officer of Amazon Goldsands Ltd.(OTCBB – (AZNG)), as well as Constitution Mining Corp (OTCC – (CMIN)). Since 2006, Mr. Phillippe has served as Chief Financial Officer of Exchequer Resource Corp. (TSX/NEX – (EXQ.H)) as well as Chief Financial Officer and Secretary of Bold Ventures Inc. (TSX – (BOL.V)).

Our Scientific Advisory Board

Professor Paul A. Wender

Professor Paul A. Wender

Bergstrom Professor of Chemistry, Department of Chemistry, Stanford University

Dr. Paul A. Wender is Bergstrom Professor of Chemistry at Stanford University and is recognized as a world-leader in the field of drug transport research. Paul has been especially active in elucidating drug delivery and novel mechanisms of transport into cells, areas that are at the cutting-edge of contemporary drug development. Professor Wender obtained his Ph.D. from Yale University in 1973 and embarked upon a career in which he has excelled in complex molecule synthesis and addressing problems of medical significance. He has been the recipient of numerous awards for his elegant research including ICI Pharmaceutical Group’s Stuart Award for Excellence in Chemistry, 1988, Pfizer Research Award for Synthetic Organic Chemistry, 1995, American Chemical Society Award for Creative work in Synthetic Organic Chemistry, 1998, H.C. Brown Award for Creative Research, as well as numerous teaching awards. In recognition of his accomplishments which span the fields of chemistry, biology and medicine, Paul was elected a Member of the National Academy of Science in 2003.

Professor Stephen Hanessian, F.R.S.C., O.C.

Isis Pharmaceuticals Research Chair, Department of Chemistry, University of Montreal

Dr. Stephen Hanessian is McConnell Professor of Chemistry at the University of Montreal and holds the NSERCC Chair in Medicinal Chemistry. Since 2000, Dr. Hanessian has, concurrently, been active as an Adjunct Professor at the University of California, Irvine. Steve has been internationally recognized for his innovative contributions in the field of medicinal chemistry by many awards, including the Wolfrom Award (American Chemical Society), the 1996 Canada Gold Medal for Science and Engineering (Canada’s highest award for scientific achievement), and has been made an Officer of the Order of Canada. His prodigious output is exemplified by principal inventorship in over 25 patents, authorship on more than 400 papers, and the training of hundreds of scientists. Steve’s knowledge of drug design, and the chemistry of amino acids, peptides and mimics, as well as molecular recognition, will directly impact Advanced Proteome Therapeutics’ objective of establishing a pipeline of protein products to address diseases that remain inadequately treated by existing therapeutics.

Professor Stephen G. Withers

Khorana Chair of Biological Chemistry, Chemistry Department, University of British Columbia

Dr. Stephen G. Withers is Khorana Professor of Chemistry and Biochemistry at the University of British Columbia, where he holds joint appointments in the Department of Chemistry and Department of Biochemistry and Molecular Biology. Dr. Withers is internationally recognized for his research on enzyme mechanisms, particularly enzymes that process oligosaccharides. His research in this area has been recognized by the Corday Morgan Medal of the Royal Society of Chemistry, U.K. (1989), the Merck Award for Organic Chemistry and Biochemistry of the Canadian Society for Chemistry (1989), the 2002 Whistler Award of the International Carbohydrate Organization, and the Rutherford Medal of the Royal Society of Canada (1993). Steve’s expertise in the area of kinetics and mechanisms of enzyme action mesh well with the capabilities required to achieve the mission of the Company.